Savaysa vs. Lovenox
See how Savaysa and Lovenox compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Savaysa is a once-daily pill for stroke prevention in atrial fibrillation and for treating blood clots, while Lovenox is an injectable used mainly for short-term clot prevention after surgery or a heart attack.
Both drugs raise bleeding risk, but Savaysa carries a boxed warning against use in atrial fibrillation patients whose kidneys work very well.
Lovenox is generally far less expensive than Savaysa, though it requires self-injection instead of a swallowed tablet.
Savaysa vs. Lovenox Drug Summary
Savaysa
Savaysa (edoxaban) is a factor Xa inhibitor, an oral anticoagulant that lowers stroke risk in people with nonvalvular atrial fibrillation and treats deep vein thrombosis (DVT) and pulmonary embolism (PE). It comes as a tablet taken once a day, with the dose adjusted for kidney function and body weight.
Lovenox
Lovenox (enoxaparin) is a low molecular weight heparin, an injectable anticoagulant used to prevent and treat blood clots such as DVT and PE, and to help prevent complications during certain heart attacks. It is given as a subcutaneous injection, with dosing and frequency depending on the reason it is prescribed.
Savaysa vs. Lovenox Side Effects
Savaysa
Lovenox
Savaysa vs. Lovenox Dosage
Savaysa
Lovenox
| STAGE | DOSE | WHEN |
| Starting dose | 60 mg once daily | At the start |
| Maximum dose | 30 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 30 mg every 12 hours | At the start |
| Maximum dose | 30 mg IV bolus once | If needed |
| Dose changes | 3 increases | As tolerated |
Savaysa
| STAGE | DOSE | WHEN |
| Starting dose | 60 mg once daily | At the start |
| Maximum dose | 30 mg once daily | If needed |
| Dose changes | 1 increase | As tolerated |
Lovenox
| STAGE | DOSE | WHEN |
| Starting dose | 30 mg every 12 hours | At the start |
| Maximum dose | 30 mg IV bolus once | If needed |
| Dose changes | 3 increases | As tolerated |
Savaysa vs. Lovenox Indications
Savaysa
Savaysa is FDA-approved to lower the risk of stroke and blood clots in people with nonvalvular atrial fibrillation, and to treat DVT and PE after an initial period on an injectable blood thinner. It is not approved for people with mechanical heart valves or antiphospholipid syndrome.
Reduce stroke and systemic embolism risk in nonvalvular atrial fibrillation
Treatment of deep vein thrombosis (DVT)
Treatment of pulmonary embolism (PE)
Lovenox
Lovenox is FDA-approved to prevent DVT after hip, knee, or abdominal surgery, and in certain medical patients at risk for clots. It also treats existing DVT and PE, and is used with aspirin for unstable angina and heart attacks including STEMI.
DVT prevention after hip or knee replacement surgery
DVT prevention after abdominal surgery
Treatment of DVT and PE
Savaysa vs. Lovenox Pros and Cons
Savaysa
Savaysa offers simple once-daily oral dosing without routine blood monitoring, but it carries a boxed warning limiting its use in atrial fibrillation patients with very good kidney function. It also needs several days of injectable anticoagulant before it can be started for a new DVT or PE.
Pros
Taken as a pill once a day, no injections
No routine blood monitoring required
One dose reduction covers both renal and weight adjustments
Cons
Boxed warning: not for AF patients with CrCL over 95 mL/min
Needs 5 to 10 days of injectable anticoagulant first for DVT/PE
Typically $483 to $561 per month, more than generic enoxaparin
Lovenox
Lovenox works right away without a lead-in drug and has decades of use across surgical and cardiac care, but it must be injected rather than swallowed. It carries its own boxed warning about spinal or epidural bleeding during certain procedures.
Pros
No lead-in anticoagulant needed before starting
Generic enoxaparin often costs $30 to $150 a month, well below Savaysa
Long track record in surgery and heart attack care
Cons
Requires self-injection, often twice a day
Boxed warning for spinal or epidural hematoma risk
Not approved for long-term stroke prevention in atrial fibrillation
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.